Healthcare of Ontario Pension Plan Trust Fund Has $55.17 Million Stock Position in Boston Scientific Corporation $BSX

Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 886.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 578,603 shares of the medical equipment provider’s stock after purchasing an additional 519,946 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Boston Scientific were worth $55,170,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Eventide Asset Management LLC boosted its position in Boston Scientific by 8.2% during the fourth quarter. Eventide Asset Management LLC now owns 40,471 shares of the medical equipment provider’s stock valued at $3,870,000 after purchasing an additional 3,055 shares during the last quarter. Entropy Technologies LP boosted its position in Boston Scientific by 137.5% during the fourth quarter. Entropy Technologies LP now owns 155,026 shares of the medical equipment provider’s stock valued at $14,782,000 after purchasing an additional 89,743 shares during the last quarter. Evelyn Partners Investment Management LLP boosted its position in Boston Scientific by 12.1% during the fourth quarter. Evelyn Partners Investment Management LLP now owns 141,888 shares of the medical equipment provider’s stock valued at $13,529,000 after purchasing an additional 15,353 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Boston Scientific by 31.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock valued at $1,052,247,000 after buying an additional 2,668,230 shares in the last quarter. Finally, Ally Financial Inc. bought a new position in Boston Scientific during the fourth quarter valued at about $1,049,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

BSX has been the topic of several recent research reports. Needham & Company LLC restated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a report on Monday, May 18th. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a report on Thursday, May 28th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a report on Friday. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Finally, Mizuho cut their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific Trading Down 0.2%

Boston Scientific stock opened at $46.83 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The business’s 50-day simple moving average is $56.37 and its 200-day simple moving average is $74.78. The firm has a market capitalization of $69.60 billion, a PE ratio of 19.59, a PEG ratio of 0.89 and a beta of 0.56. Boston Scientific Corporation has a 52 week low of $45.99 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.